Itraconazole for Deep Mycoses: Preliminary Experience in Mexico

Lavalle, P.; Suchil, Patricia; Ovando, Francisco De; Reynoso, Samuel

doi:10.1093/clinids/9.supplement_1.s64

Cited by 54 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our criterion for cases with extensive lesions is to administer itraconazole initially until maximum lesion reduction has been achieved and then use cryosurgery to remove the remaining active lesions [25]. Our results are very similar to those reported in the literature [26–31].…”

Section: Discussionsupporting

confidence: 79%

Chromoblastomycosis: clinical and mycologic experience of 51 cases

Bonifáz

Carrasco‐Gerard

Saúl

2001

Mycoses

188

166

View full text Add to dashboard Cite

This is a study of 51 cases of chromoblastomycosis detected in a 17-year period, all of which were clinically and mycologically proven by direct examinations, cultures and biopsies. The therapeutic results of the various treatments used are reported. Most cases were males (36 of 51; 70%), the mean age was 35 years and farmers predominated (74%); the most frequent lesions were in the lower limbs (54%). Major clinical presentations were nodular (41%) and verrucous (26%). The principal aetiologic agent isolated was Fonsecaea pedrosoi (90%). Overall results of the various treatments were as follows: 31% were cured, 57% improved and 12% failed. The best results were obtained with cryosurgery for small lesions, with itraconazole for large ones, and in some cases the combination of both treatments.

show abstract

Section: Discussionsupporting

confidence: 79%

Chromoblastomycosis: clinical and mycologic experience of 51 cases

Bonifáz

Carrasco‐Gerard

Saúl

2001

Mycoses

188

166

View full text Add to dashboard Cite

show abstract

“…Improvement in mycetoma caused by Madurella grisea also was obtained. Similarly, encouraging data on the activity of itraconazole in the treatment of aspergillosis, blastomycosis, candidiasis (systemic and mucocutaneous), chromomycosis, coccidioidomycosis, and sporotrichosis have been reported by several investigators (77,100,170,217). In one study of particular interest, itraconazole was found to be more active than ketoconazole in the antifungal prophylaxis of patients with severe granulocytopenia (306).…”

Section: Antifungal Imidazoles Under Developmentmentioning

confidence: 90%

Overview of medically important antifungal azole derivatives

1988

View full text Add to dashboard Cite

Fungal infections are a major burden to the health and welfare of modern humans. They range from simply cosmetic, non-life-threatening skin infections to severe, systemic infections that may lead to significant debilitation or death. The selection of chemotherapeutic agents useful for the treatment of fungal infections is small. In this overview, a major chemical group with antifungal activity, the azole derivatives, is examined. Included are historical and state of the art information on the in vitro activity, experimental in vivo activity, mode of action, pharmacokinetics, clinical studies, and uses and adverse reactions of imidazoles currently marketed (clotrimazole, miconazole, econazole, ketoconazole, bifonazole, butoconazole, croconazole, fenticonazole, isoconazole, oxiconazole, sulconazole, and tioconazole) and under development (aliconazole and omoconazole), as well as triazoles currently marketed (terconazole) and under development (fluconazole, itraconazole, vibunazole, alteconazole, and ICI 195,739).

show abstract

“…Mild or moderate forms may reach cure after 6-12 months [9,11,58,99]. Severe cases tend to present great improvement after several months of therapy, but it is rare to achieve a full, long-lasting cure.…”

Section: Itraconazolementioning

confidence: 99%

Chromoblastomycosis: still a therapeutic challenge

Castro

Andrade

2010

Expert Review of Dermatology

View full text Add to dashboard Cite

Chromoblastomycosis is a chronic cutaneous and subcutaneous infection caused by the traumatic implantation of certain dematiaceous fungi (presently classified among the Herpotrichiellaceae family) through the skin, and should not be confused with mycoses caused by other types of pigmented fungi, such as phaeohyphomycosis or mycetomas. Host defense mechanisms in chromoblastomycosis are still not completely understood, and recent studies have helped to improve knowledge. One of the most characteristic features of the disease is unresponsiveness to treatment. Oral itraconazole and terbinafine have both presented results consistent enough to be considered as 'methods of choice', but therapy still poses a great challenge. Cryosurgery with liquid nitrogen is indicated to treat the disease in an isolated or combined method. New drugs such as posaconazole and voriconazole have been used in a limited number of cases, and it is not possible to draw a comparison between the presently used methods and these new drugs.

show abstract

Itraconazole for Deep Mycoses: Preliminary Experience in Mexico

Cited by 54 publications

References 0 publications

Chromoblastomycosis: clinical and mycologic experience of 51 cases

Chromoblastomycosis: clinical and mycologic experience of 51 cases

Overview of medically important antifungal azole derivatives

Chromoblastomycosis: still a therapeutic challenge

Contact Info

Product

Resources

About